摘要
目的探讨阿托伐他汀钙对蛛网膜下腔出血脑血管痉挛患者PKC、CRP、FABP的影响。方法选择100例于2016年1月~2018年12月在我院神经外科治疗的蛛网膜下腔出血导致脑血管痉挛的患者作为观察对象,采用随机数表法将100例入院患者分为两组,各50例。其中对照组患者入院后实施降颅内压、抗感染、镇静等常规治疗,治疗组患者入院后均在对照组的基础上口服阿托伐他汀钙治疗。比较两组患者的疗效、蛋白激酶C(PKC)、C反应蛋白(CRP)、脂肪酸结合蛋白(FABP),血管性血友病因子(vWF)、基质金属蛋白酶-9(MMP-9)、基质金属蛋白酶-2(MMP-2)和发生的药物不良反应率。结果治疗组总有效率明显高于对照组(82.00%>58.00%)(P<0.05)。治疗后,两组患者PKC、CRP、FABP、vWF、MMP-2以及MMP-9均较治疗前发生明显的降低,且治疗组各指标降低幅度较对照组更高,差异均有统计学意义(P<0.05)。此外,对照组治疗后出现1例恶心呕吐、1例低血压、3例颜面潮红,不良反应为10.00%;而治疗组治疗后出现2例恶心呕吐、2例低血压、2例颜面潮红,不良反应为12.00%;两组数据对比,差异无统计学意义(P>0.05)。结论阿托伐他汀钙对蛛网膜下腔出血脑血管痉挛疗效确切,同时不增加不良反应发生率,值得临床推广应用。
Objective To investigate the effect of atorvastatin calciumin on PKC, CRP and FABP in patients with subarachnoid hemorrhage cerebral vasospasm. Methods One hundred patients with cerebral vasospasm caused by subarachnoid hemorrhage in the Department of Neurosurgery of our hospital from January 2016 to December 2018 were selected as the observation objects. They were randomly divided into two groups, 50 cases in each group. Patients in the control group were given conventional treatment such as reducing intracranial pressure, anti infection and sedation after admission, while patients in the treatment group were treated with atorvastatin calcium on the basis of the control group. Control group was treated with anti-infection, sedation and cough, intracranial pressure. Treatment group was treated with atorvastatin calciumin based on control group. After treatment, clinical efficacy, the levels of PKC, CRP, FABP, vWF, MMP-9, MMP-2 and the rate of adverse reactions were compared between two groups. Results The total effective rate in treatment group was higher than that in control group(82.00%>58.00%)(P<0.05). After treatment, PKC, CRP, FABP, vWF, MMP-2 and MMP-9 in the two groups were significantly decreased compared with those before treatment,and the reduction range of each index in the treatment group was higher than that in the control group(P<0.05). The levels of MMP-2 and MMP-9 in the treatment group were significantly lower than those in the control group(P<0.05). In addition, 1 case of nausea and vomiting, 1 case of hypotension and 3 cases of facial flushing occurred in the control group after treatment, with adverse reactions of 10.00%;while in the treatment group, there were 2 cases of nausea and vomiting, 2 cases of hypotension, 2 cases of facial flushing, the adverse reactions were 12.00%;there was no statistically significant difference between the two groups(P>0.05). Conclusion Atorvastatin calciumin improve the clinical efficacy of subarachnoid hemorrhage patients with cerebral vasospasm, and do not increase the incidence of adverse reactions, which is worthy of clinical application.
作者
侯鹏飞
刘展会
张睿
程文佳
HOU Peng-fei;LIU Zhan-hui;ZHANG Rui;CHENG Wen-jia(Department of Neurosurgery,Ninth Hospital of Xi’an City,Xi’an 710054,China;Department of Pathology,Ninth Hospital of Xi’an City,Xi’an 710054,China)
出处
《哈尔滨医科大学学报》
CAS
2020年第2期152-155,共4页
Journal of Harbin Medical University
基金
陕西省重点研发计划项目(2018SF-093)。
关键词
阿托伐他汀钙
蛛网膜下腔出血
脑血管痉挛
atorvastatin calciumin
subarachnoid hemorrhage
cerebral vasospasm
